>>> Johnson & Johnson beats by $0.02, reports revs in-line; guides FY16 EPS abov

--> JNJ no pre market

Johnson & Johnson beats by $0.02, reports revs in-line; guides FY16 EPS above consensus, revs below consensus
  • Reports Q4 (Dec) earnings of $1.44 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $1.42; revenues fell 2.4% year/year to $17.81 bln vs the $17.86 bln Capital IQ Consensus. Operational sales results increased 4.4% and the negative impact of currency was 6.8%. Domestic sales increased 8.0%. International sales decreased 11.7%, reflecting operational growth of 1.2% and a negative currency impact of 12.9%. Ex-acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 7.8%, domestic sales increased 13.4% and international sales increased 2.9%.
    • Worldwide Consumer sales of $13.5 billion for the full-year 2015 represented a decrease of 6.8% versus the prior year, consisting of an operational increase of 2.7% and a negative impact from currency of 9.5%. Domestic sales increased 2.5%; international sales decreased 11.9%, which reflected an operational increase of 2.7% and a negative currency impact of 14.6%.
    • Worldwide Pharma sales of $31.4 billion for the full-year 2015 represented a decrease of 2.7% versus the prior year with an operational increase of 4.2% and a negative impact from currency of 6.9%. Domestic sales increased 5.2%; international sales decreased 12.0%, which reflected an operational increase of 3.0% and a negative currency impact of 15.0%.
    • Worldwide Medical Devices sales of $25.1 billion for the full-year represented a decrease of 8.7% versus the prior year consisting of an operational decrease of 1.4% and a negative currency impact of 7.3%. Domestic sales decreased 1.0%; international sales decreased 14.8%, which reflected an operational decrease of 1.7% and a negative currency impact of 13.1%.
  • Co issues guidance for FY16, sees EPS of $6.43-6.58, excluding non-recurring items, vs. $6.40 Capital IQ Consensus; sees FY16 revs +2.3-3.5% to $70.8-71.5 bln (+4.5-6% adj.) vs. $71.99 bln Capital IQ Consensus.

>>> DuPont beats by $0.01, reports revs in-line; guides FY16 EPS below consensus

--> DD no indication for now

DuPont beats by $0.01, reports revs in-line; guides FY16 EPS below consensus
  • Reports Q4 (Dec) earnings of $0.27 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.26; revenues fell 9.4% year/year to $5.3 bln vs the $5.31 bln Capital IQ Consensus. Excluding currency, sales declined 1 %. Currency negatively impacted sales by an additional 8 %. Segment pre-tax operating earnings of $553 million included $170 million, or $0.17 per share, of negative impact from currency.
    • Growth in Industrial Biosciences and Nutrition & Health was more than offset by declines in Agriculture, Performance Materials, Safety & Protection and Electronics & Communications.
  • Co issues downside guidance for FY16, sees EPS of $2.95-3.10, excluding non-recurring items, vs. $3.13 Capital IQ Consensus, including an expected benefit of $0.64 per share from the 2016 global cost savings and restructuring plan.
    • Current difficult global economic conditions in agriculture and slower growth in emerging markets are expected to continue, challenging the co's sales growth in 2016. The increase in the expected benefit results from identification of additional savings that will be delivered from the existing plans, including previously announced employee reduction estimates. The benefit from the 2016 global cost savings and restructuring plan will be weighted toward 2H16 as specific actions continue to be implemented in the first and second quarters.
    • 2016 operating earnings also includes ~$0.30 per share of estimated negative currency impact due to the continued strengthening of the U.S. dollar, pressuring both the top and bottom line. A higher base tax rate, reflecting the expected geographic mix of earnings, is expected to negatively impact operating earnings by $0.05 - $0.10 per share. The currency impact is expected to be most significant in the first half of the year due to a further weakening of the U.S dollar. Given the seasonality of the co's operating earnings from Agriculture in the northern hemisphere, the company anticipates ~two-thirds of the expected currency impact to occur in 1H16.
  • Merger with Dow (DOW) expected to close in 2H16

>>> SunEdison: Greenlight Capital discloses increased 7.8% active stake, details

SunEdison: Greenlight Capital discloses increased 7.8% active stake, details recent discussions with representatives of the Board

From January 15, 2016 to January 25, 2016, representatives of the Reporting Persons engaged in discussions with representatives of the Company's board of directors, including the Chairman, and other representatives of the Company to discuss (x) the performance of the Company's senior management team, (y) the composition of the Board and (z) future issuances of the Company's equity and equity-linked securities.
  • Specifically, Greenlight has proposed that (x) the Company appoint a person designated by Greenlight to the Board (as well as to the Board's Nominating and Corporate Governance and Finance and Investment Committees) as an independent director, and (y) the Company's bylaws be amended to provide that, for a period of two (2) years following the date of such bylaw amendment, the Company would not be permitted to make equity issuances without a supermajority vote of the Board, except in limited circumstances. To date, no understanding has been reached between Greenlight and the Company with respect to these issues.
  • Greenlight intends to evaluate on an ongoing basis its investment in the Company and its options with respect to such investment. In connection with such evaluation, Greenlight may seek additional calls and meetings with members of the Board and/or senior management of the Company, or communicate publicly or privately with other stockholders or third parties to indicate Greenlight's views on issues relating to the strategic direction undertaken by the Company and other matters of interest to stockholders generally, including management. As part of such evaluation and any such discussions, Greenlight may make recommendations, suggestions or proposals to the Company that may relate to or result in one or more of the transactions specified in clauses (a) through (j) of Item 4 of Schedule 13D, including but not limited to: changes in the strategic direction of the Company as a means of enhancing shareholder value, changes to the Board, changes to the Company's senior management, changes to the Company's charter or bylaws, acquisitions or dispositions of securities of the Company, changes in the Company's capital structure or dividend policy, and the sale of material assets or another extraordinary corporate transaction, including a sale of the Company.

(MS) Best Business Models In Europe

We launch the first version of our 'Best Business Models' list in Europe, which highlights 25 leaders from across each industry group with high and sustainable RNOA and strong balance sheets. We believe this stock selection approach is particularly relevant in the current volatile environment.


Launching the 'Best Business Models' list in Europe
We introduce the first version of our 'Best Business Models' list in Europe, which highlights 25 leaders from across each industry group for the long-term investor. The companies in the list are large, leading franchises in their sectors, with high and sustainable RNOA and strong balance sheets. They have been chosen through a two-part selection process – a quantitative screen and qualitative input from our analysts.

Our 'Best Business Models' basket would have outperformed MSCI Europe by 190% since 2008
The median stock in our 'Best Business Models' basket has outperformed MSCI Europe by 190% over the past eight years and also consistently outperformed European value and, more relevantly, growth indices since 2009.

(DBK) French Telco : French mobile potential consolidation a win, win, win situ

French mobile potential consolidation a win, win, win situation?

Reiterating Buy on Orange/NUME, Iliad Buy from Hold, TPs E17.9/50/266 resp.
Following Journal de Dimanche (JDD) speculation, Orange confirmed talks with Bouygues aimed at merging with Bouygues Telecom (B.T.). The French regulator/government are open to it if competition is preserved, Orange’s
market share unchanged, investments enhanced and jobs preserved. We show in this 50-page report how a deal could be structured so that Bouygues, the government and three remaining players (Orange, NUME, Iliad) all win. We increase TPs by 12% for Iliad and 3% for Orange while NUME’s is unchanged.

Expect Iliad to pay E4.2bn, NUME E2.6bn, Orange E2.7bn; no Orange dilution
We assume E10bn will be paid for B.T.: E6bn in cash and E4bn in existing Orange shares (2.2% bought from the government diluted to 20.8% but still maintaining 3 seats on the BOD, 7.6% bought on the market), with the bulk of B.T. subscribers, spectrum, mobile antennas, shops and employees of the related assets bought by lliad and Numericable for E4.2bn and E2.6bn respectively, which leaves E2.7bn for Orange. Resulting debt/EBITDA would be 2x pre-market repair benefits for Orange, 3.7x for NUME and 2.7x for Iliad, with market shares balanced: Orange at 39% in mobile post-paid vs. 37% now, NUME at 34% vs. 29% and Iliad at 25% vs. 18%, which is extremely important for the health of the French market: reaching its 25% l/t target through the acquisition and needing to protect its new high value customers should mitigate Iliad’s aggressiveness but not kill its maverick spirit, which is precious to regulators. Spectrum shares – 40-33-27% resp. (37-32-32 low frequencies) – would mirror mobile market shares, allowing Iliad to grow further.

Market repair value creation E7.6/3.2/0.8bn ORA/Iliad/NUME on existing clients
We estimate cumulated E1.3bn EBITDA will be generated by B.T.’s assets once sold to the three players vs. E0.9bn B.T. EBITDA guidance for 2016. This implies a E0.4bn run rate of synergies, or E2.5bn NPV, to be added to the market repair benefit on the existing client base. Resultant post-synergies pre-market repair) EV/EBITDA paid would be 7.2x for Iliad, 7.5x for NUME and 9.8x for Orange, reflecting lower integration risks taken vs. the other two players. We see mobile ARPU trending to E23.4 by 2020 for Orange and NUME, 9% above our (pre-consolidation) models: 0.8/0.9% CAGR 2015-20, below French inflation forecasts, is consistent with Orange CEO commitment not to increase prices. We expect additional benefits from lower churn and handset subsidies, in line with Austria. We embody the related value creation in our target prices, assigning a 70% probability (given more visibility on the potential consolidation) to consolidation. A government blessing could well be aimed at seeing Orange active in cross-border consolidation. Iliad/Xavier Niel are looking for assets outside France too. If France provides resources for expansion, a healthy French market is needed by all players.

Iliad a play on consolidation, Orange/NUME have upside even if it fails; risks
We see 13% upside potential to TP for Orange, 18% for Iliad and 44% for NUME, assuming 70% probability of consolidation. Should consolidation fail, upsides would be +3/-3/+39% respectively and, if it succeeds, +17/+26/+48%. We use DCF-based SOTP to derive our target price, with WACCs ranging from 7% to 13.3% (Orange’s African assets) and g from 0% to 5%. See details in the note. Risks: 1) consolidation talks stop, 2) M&A destroying value, 3) Orange/Iliad potential buyers in cross-border mergers. We argue consolidation should not affect Orange in the fibre roll-out because Iliad’s roll-out plans would be above Iliad’s plus Bouygues’ current ones.